Member Info for champagnecharlie

That said, I've been looking at the 2021 results (RNS of 3 November) and am intrigued by the turnround in H2. On my back-of-an-envelope estimate, the automation and test systems division (QM, TED and Weston) made a pretax profit of £450K or more in Q4 alone. This year, assuming the other two divisions collectively manage to break even, PIP as a whole should be capable of producing well over £1m profit pretax, perhaps even £1.5m. The tax charge should be negative because of R&D tax credits. Given the claimed prospects for future growth, on a market cap of less than £5m (c£7.5m fully diluted) that doesn't look altogether unattractive.

JMcJ - I'm not 100% sure, but I think it went something like this: GW paid PIP the £197K upfront, i.e. before the sale was completed, rather than on completion as you'd expect. (I'm guessing that PIP may have had some cash flow issues at the time.) Initially, that was treated as a temporary increase to GW's loan: then, on completion, the loan increase was wiped out and PIP retained the £197K as consideration in the normal way.
All past history now, but I think we must accept that PIP is in effect a vehicle for GW.

Chad: authorities come down to Miandoum following the fire at an oil site
6 November 2021
The provincial secretary general of Logone Oriental, Ngana Djékila, accompanied by a large delegation, paid a visit to the Ngalamba oil site near Miandoum to see firsthand the damage caused since yesterday by the fire.
After some expectations due to security predispositions, the provincial secretary general and some members of his delegation were treated to a guided tour of the tanks damaged by the fire, which was only brought under control this morning by the Koudalwa technical team.
At the end of this visit, Ngana Djékila, representing the governor, primed us on the purpose of this trip. For him, the causes of this fire are not known until now.
He deplores this situation causing an economic loss for the country and reassures that analyses will be made in the days to come by experts to measure the various consequences of this phenomenon on the life of the populations surrounding this site.
The provincial secretary general calls on the inhabitants of the surrounding villages of this site to exercise restraint because for him, calm has returned.
https://www.alwihdainfo.com/Tchad-descente-des-autorites-a-Miandoum-suite-a-l-incendie-dans-un-site-petrolier_a108567.html

One's left wondering what is fake news and what isn't. On balance I tend to think that the fire was probably real after all. Whether it was sabotage, or what, is another matter.

S20 - Brilliant, many thanks for posting this, but you left out the all-important first word from the headline!

" IF Qualcomm acquires a DMS player, we think Seeing Machines is more likely than Smart Eye"

maximus - Be my guest - but the OP started with an assumption ($50m IPO) and from that, concluded that the value of TEK "should be" £x. All I was doing was to point out the logical fallacy of drawing *factual* conclusions from *blue sky* assumptions.
We can "best guess" all we like but, as I say, time will tell. And looking longer term, the IPO is only a snapshot anyway; what's really of interest is that Lucyd (and the other TEK investments) should prosper and become profitable. Or get sold off, of course.
Old Spanish proverb: Patience fleas, the night is long.

cm, no disrespect but "reasonably conservative" is in your judgment, it's not a statement of fact. I'll be delighted if you turn out to be right, and I'm not saying you necessarily won't, but frankly, when push comes to shove, you've nothing concrete to go on. (And let's face it, the crowdfunding at $20m was out there for 3 months and didn't exactly fly.)
Time will tell. Either way, I'm happy to hold my TEK shares for the long term irrespective of the Lucyd flotation.

puma33 - Sorry, but you can't simply pick a number out of thin air and then use it to justify your calculations: that's just wishful thinking, putting the cart before the horse. So no, you're not right - in that you're arguing from a false premise. Why $50m? The IPO could just as easily be at $100m - or at $5m.
In time, if Lucyd thrives, then perhaps. The future holds loads of promise for Lucyd and indeed all TEK's other portfolio companies, but let's not go jumping the gun.

String these three words together as one and substitute for the dots:

directors
talk
interview

In this article dated 21 July 2020, a little over a year ago, Colin Barnden expresses the view that the MBux in Merc S Class is SEE. On the other hand, he is distinctly unimpressed with Mercedes strategy:
https://www.eetasia.com/blog-what-is-going-on-at-mercedes/

ah, I see they have filtered the word, though not the whole message - how childish..........

Here we go: Qualcomm digital ****pits. There.

O/T Sorry, but why is everyone so coy about writing ****pit? Perfectly good word and not rude at all. Does LSE suffer from hypersensitive filtering? I'll post again and see if it gets filtered.....

TopCatz, fully share your sentiments. Sorry though, but could you explain to us oldies what "Totally WG" means?

BOJO2020 - To my mind that is exactly on point, no need to wait for Grail. If Grail/Illumina at some point express an interest in getting together with AGL, so much the better: but everything so far suggests that Parsortix should work fine in combination with good old PSA testing and, subject to AGL making a watertight case as you say, reduce the false positives dramatically. Potential cost saving to the NHS alone should be eye-watering, let alone the US and the rest of the world.

PJT12: The RNS specifically refers to a blood test to assess the risk of prostate cancer
"ahead of prostate tissue biopsy"
and that this offers
"a unique opportunity to triage men with elevated PSA"
while avoiding the need for invasive core tissue biopsy.

See also this summary from Queen Mary's
hTTps://www.qmul.ac.uk/bci/the-pinprick-that-improves-cancer-diagnosis/
which makes no mention of an initial Grail-type test and suggests that Parsortix would be simply a companion diagnostic following an elevated PSA reading.

PJT12 - That's not the impression I get from the RNS, but I'm no expert and I think you would have to ask AN.

PJT12 - You say that an early highly sensitive (best in class) cancer detection system is not Parsortix's intended market. Indeed, that was what we have always understood. But what I find really exciting is that Thursday's RNS appears to change that:
"The Placing allows an expansion of ANGLE's activities to include running prostate cancer studies with the potential to address a large market for a blood test to assess the risk of prostate cancer ***ahead of prostate tissue biopsy*** [my emphasis], which is an invasive procedure where some 75% of biopsy procedures are negative for cancer. Prostate cancer clinical tests are a c.US$6.7 billion per annum market (United States only), with 1 million men having a Prostate Specific Antigen ("PSA") test, and 250,000 new cases in 2021 in the US alone, with the average costs of prostate biopsy of c.US$2,000. The procedure has a high incidence of complications, with 98% having some side effects, 32% moderate and 1.4% major complications. Post-biopsy sepsis occurs in 2-5% of cases with up to 25% of these requiring to be admitted to the ICU. Liquid biopsy offers ***a unique opportunity to triage men with elevated PSA*** avoiding the need for invasive core tissue biopsy for the 90% of patients with benign or indolent disease. The Company has identified this as an area of opportunity and intends to use the proceeds of the Placing to pursue it further."

As I understood Traygam's post, he (or she) was asking if there were any current trials he might be able to join, perhaps even in place of his forthcoming op. Sadly, this 9-year old RNS won't achieve that. It wasn't even a formal trial under the usual controlled conditions, just a demonstration that Parsortix is able to isolate colorectal cancer cells. So far I don't think there have been any reports of proper peer-reviewed trials with Parsortix for colorectal cancer, and moreover there are no peer-reviewed publications or posters at all on Angle's website earlier than 2014.
Hope everything goes well Traygam, good luck.

Gerkin - Sorry to disappoint, but that report on "colon cancer detection" - more accurately, the ability of Parsortix to capture colon cancer cells - was in an RNS from March 2012, over nine years ago: https://www.lse.co.uk/rns/AGL/parsortix-validation-for-colon-cancer-1iir72ldl8dyauq.html

On ADVFN, each company may have more than one discussion board, but typically only one is current. When you search a company, a little box will come up at the right which you can check to make it a "favourite".

Personally, I've found that the way to go is to tick the "favourites" box for all relevant boards. You then end up with a "favourite boards summary page" which you bookmark, and on which new postings show up as and when. Quite easy once you're used to it.